151 related articles for article (PubMed ID: 38358343)
1. PCSK9 dysregulates cholesterol homeostasis and triglyceride metabolism in olanzapine-induced hepatic steatosis via both receptor-dependent and receptor-independent pathways.
Huang P; Ran J; Zhu W; Dai W; Tang Y; Lian P; Huang X; Li R
FASEB J; 2024 Feb; 38(4):e23464. PubMed ID: 38358343
[TBL] [Abstract][Full Text] [Related]
2. Metformin Ameliorates Hepatic Steatosis induced by olanzapine through inhibiting LXRα/PCSK9 pathway.
Zhu W; Ding C; Huang P; Ran J; Lian P; Tang Y; Dai W; Huang X
Sci Rep; 2022 Apr; 12(1):5639. PubMed ID: 35379885
[TBL] [Abstract][Full Text] [Related]
3. A promising therapy for fatty liver disease: PCSK9 inhibitors.
Han L; Wu L; Yin Q; Li L; Zheng X; Du S; Huang X; Bai L; Wang Y; Bian Y
Phytomedicine; 2024 Jun; 128():155505. PubMed ID: 38547616
[TBL] [Abstract][Full Text] [Related]
4. PCSK9 mediates dyslipidemia induced by olanzapine treatment in schizophrenia patients.
Huang J; Xiao J; Peng Z; Shao P; Sun M; Long Y; Wang X; Shen M; Kang D; Yang Y; Peng X; Wang W; Xie P; Shao T; Zhao J; Wu R
Psychopharmacology (Berl); 2022 Jan; 239(1):83-91. PubMed ID: 35029705
[TBL] [Abstract][Full Text] [Related]
5. Liver fat accumulation is associated with circulating PCSK9.
Ruscica M; Ferri N; Macchi C; Meroni M; Lanti C; Ricci C; Maggioni M; Fracanzani AL; Badiali S; Fargion S; Magni P; Valenti L; Dongiovanni P
Ann Med; 2016 Aug; 48(5):384-91. PubMed ID: 27222915
[TBL] [Abstract][Full Text] [Related]
6. Olanzapine causes non-alcoholic fatty liver disease via inhibiting the secretion of apolipoprotein A5.
Li R; Zhu W; Huang P; Ding C; Tang Y; Lian P; Huang X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Jun; 47(6):730-738. PubMed ID: 35837772
[TBL] [Abstract][Full Text] [Related]
7. Diet-induced hepatic steatosis abrogates cell-surface LDLR by inducing
Lebeau PF; Byun JH; Platko K; MacDonald ME; Poon SV; Faiyaz M; Seidah NG; Austin RC
J Biol Chem; 2019 Jun; 294(23):9037-9047. PubMed ID: 31004037
[TBL] [Abstract][Full Text] [Related]
8. Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: A single lipid center real-world experience.
Scicali R; Di Pino A; Urbano F; Ferrara V; Marchisello S; Di Mauro S; Scamporrino A; Filippello A; Rabuazzo AM; Purrello F; Piro S
Nutr Metab Cardiovasc Dis; 2021 Mar; 31(3):869-879. PubMed ID: 33549441
[TBL] [Abstract][Full Text] [Related]
9. Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line.
Ruscica M; Ricci C; Macchi C; Magni P; Cristofani R; Liu J; Corsini A; Ferri N
J Biol Chem; 2016 Feb; 291(7):3508-19. PubMed ID: 26668321
[TBL] [Abstract][Full Text] [Related]
10. PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse Liver.
Demers A; Samami S; Lauzier B; Des Rosiers C; Ngo Sock ET; Ong H; Mayer G
Arterioscler Thromb Vasc Biol; 2015 Dec; 35(12):2517-25. PubMed ID: 26494228
[TBL] [Abstract][Full Text] [Related]
11. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
12. Olanzapine leads to nonalcoholic fatty liver disease through the apolipoprotein A5 pathway.
Li R; Zhu W; Huang P; Yang Y; Luo F; Dai W; Shen L; Pei W; Huang X
Biomed Pharmacother; 2021 Sep; 141():111803. PubMed ID: 34146854
[TBL] [Abstract][Full Text] [Related]
13. The Role of PCSK9 in the Pathogenesis of Non-alcoholic Fatty Liver Disease and the Effect of PCSK9 Inhibitors.
Theocharidou E; Papademetriou M; Reklou A; Sachinidis A; Boutari C; Giouleme O
Curr Pharm Des; 2018; 24(31):3654-3657. PubMed ID: 30317984
[TBL] [Abstract][Full Text] [Related]
14. Hepatic and circulating levels of PCSK9 in morbidly obese patients: Relation with severity of liver steatosis.
Emma MR; Giannitrapani L; Cabibi D; Porcasi R; Pantuso G; Augello G; Giglio RV; Re NL; Capitano AR; Montalto G; Soresi M; Cervello M
Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Dec; 1865(12):158792. PubMed ID: 32777481
[TBL] [Abstract][Full Text] [Related]
15. Dennd5b-Deficient Mice are Resistant to PCSK9-Induced Hypercholesterolemia and Diet-Induced Hepatic Steatosis.
Mobilia M; Whitus C; Karakashian A; Lu HS; Daugherty A; Gordon SM
J Lipid Res; 2022 Dec; 63(12):100296. PubMed ID: 36243100
[TBL] [Abstract][Full Text] [Related]
16. Gracilaria chorda subcritical water ameliorates hepatic lipid accumulation and regulates glucose homeostasis in a hepatic steatosis cell model and obese C57BL/6J mice.
Thakuri LS; Park CM; Kim HA; Kim HJ; Park JW; Park JC; Rhyu DY
J Ethnopharmacol; 2024 Feb; 320():117395. PubMed ID: 37952731
[TBL] [Abstract][Full Text] [Related]
17. The role of PCSK9 in NAFLD/NASH and therapeutic implications of PCSK9 inhibition.
Momtazi-Borojeni AA; Banach M; Ruscica M; Sahebkar A
Expert Rev Clin Pharmacol; 2022 Oct; 15(10):1199-1208. PubMed ID: 36193738
[TBL] [Abstract][Full Text] [Related]
18. Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue.
Roubtsova A; Munkonda MN; Awan Z; Marcinkiewicz J; Chamberland A; Lazure C; Cianflone K; Seidah NG; Prat A
Arterioscler Thromb Vasc Biol; 2011 Apr; 31(4):785-91. PubMed ID: 21273557
[TBL] [Abstract][Full Text] [Related]
19. Sauchinone controls hepatic cholesterol homeostasis by the negative regulation of PCSK9 transcriptional network.
Chae HS; You BH; Kim DY; Lee H; Ko HW; Ko HJ; Choi YH; Choi SS; Chin YW
Sci Rep; 2018 Apr; 8(1):6737. PubMed ID: 29712938
[TBL] [Abstract][Full Text] [Related]
20. PCSK9 rs11591147 R46L loss-of-function variant protects against liver damage in individuals with NAFLD.
Grimaudo S; Bartesaghi S; Rametta R; Marra F; Margherita Mancina R; Pihlajamäki J; Kakol-Palm D; Andréasson AC; Dongiovanni P; Ludovica Fracanzani A; Lori G; Männistö V; Pellegrini G; Bohlooly-Y M; Pennisi G; Maria Pipitone R; Spagnuolo R; Craxì A; Lindén D; Valenti L; Romeo S; Petta S
Liver Int; 2021 Feb; 41(2):321-332. PubMed ID: 33091218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
